Loading
A phase 1/2 trial of LYL273 in colorectal cancer, run by Lyell Immunopharma, Inc., now recruiting.
LYL273 for Patients With Relapsed or Refractory mCRC is a phase 1/2 interventional study registered as NCT05319314 by Lyell Immunopharma, Inc., with 155 participants planned, started 2022-08-01 and due to reach its primary completion in 2028-06. Interventions recorded: LYL273.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.